Clinical characteristics are shown in Table S1 and include the age at start of anti-PD-1 treatment, stage of disease, time to progression, survival on study without disease progression, method of evaluation Response Evaluation Criteria in Solid Tumors (RECIST), the types of prior therapies used for treatment, and the sites of metastatic disease. This evidence concerns the gene PDCD1 and metastatic neoplasm.